Finance

Lists
Q3 2026 earnings • released • EPS beat +59.15%
See results
BMEA:NASDAQ
Biomea Fusion Inc
$0.58
+3.47%
(+0.020) 1D
$0.58
-0.43% (-0.0025)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMEA...
Open
$0.58
High
$0.60
Low
$0.54
Mkt. cap
42.52M
Avg. vol.
2.14M
Volume
563.88K
52-wk high
$2.24
52-wk low
$0.54
EPS
-$0.31
Beta
-0.14
Shares outstanding
72.68M
No. of employees
37
Open
$0.58
High
$0.60
Low
$0.54
Mkt. cap
42.52M
Avg. vol.
2.14M
Volume
563.88K
52-wk high
$2.24
52-wk low
$0.54
EPS
-$0.31
Beta
-0.14
Shares outstanding
72.68M
No. of employees
37
News stories
From web sources and news partners
About Biomea Fusion Inc
CEO-
Employees37
Founded2017
HeadquartersSan Carlos, California, United States
SectorHealth Care
IndustryBiotechnology
Websitebiomeafusion.com
Analyst ratings
Based on 4 analysts giving stock ratings to BMEA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for BMEA in the last 3 months.
Highest
Current $0.58
$10.00 (+1,617.62%)
Average
$6.25 (+973.51%)
Lowest
$4.00 (+587.05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$4.00
+587%
11/11/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$4.00
+587%
11/11/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$7.00
+1,102.3%
11/10/2026
Kumaraguru Raja
Brookline Capital Markets
Buy
Initiated
$10.00
+1,617.6%
10/07/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$7.00
+1,102.3%
08/06/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$9.00
+1,445.9%
08/06/2026
Anupam Rama
J.P. Morgan
Sell
Maintained
-
-
03/24/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
-$0.09 / -$0.22
+59.15%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.12M
9.12M
9.14M
8.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.60M
3.65M
3.62M
4.43M
Operating expense
11.72M
12.77M
12.77M
12.96M
Total operating expenses
11.72M
12.77M
12.77M
12.96M
Operating income
-11.72M
-12.77M
-12.77M
-12.96M
Other non operating income
19.86M
-581.00K
4.12M
6.51M
EBT including unusual items
4.61M
-12.42M
-8.33M
-6.18M
EBT excluding unusual items
4.61M
-12.92M
-8.33M
-6.18M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
4.61M
-12.42M
-8.33M
-6.18M
Net profit margin
-
-
-
-
Earnings per share
-0.12
-0.17
-0.17
-0.17
Interest and investment income
-
430.00K
319.00K
267.00K
Interest expense
-3.53M
-
-
-
Net interest expenses
-3.53M
430.00K
319.00K
267.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.67M
-12.73M
-12.75M
-12.94M
Gain or loss from assets sale
-
-510.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps